No article text was recorded for this version.
on-target off-tumor toxicity
Version 1 of 132 papers39 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
- Blog: Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
- Blog: Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
- Blog: Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
- Blog: CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia
- Blog: Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy
- Blog: CD80 Antibody and MTX Co-Engineered Extracellular Vesicles Targets CD80+ Macrophages to Suppress Inflammation and Alleviate Chronic Inflammatory Diseases
- Blog: Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications
- Blog: Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
- Blog: BAP31, a promising target for the immunotherapy of malignant melanomas
- Blog: Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models
- Blog: Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma
- Blog: P03.07 Analysis of scRNAseq from the human thymus nominates genes potentially missing from central tolerance of cytotoxic T cells
- Blog: Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma
- Blog: Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy
- Blog: HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
- Blog: EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
- Blog: Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
- Blog: Identification of TCR Vβ11-2-Dβ1-Jβ1-1 T cell clone specific for WT1 peptides using high-throughput TCRβ gene sequencing
- Blog: Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
- Blog: Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing
- Blog: TIL-Derived CAR T Cells Improve Immune Cell Infiltration and Survival in the Treatment of CD19-Humanized Mouse Colorectal Cancer
- Blog: Adoptive cell therapy for cancer treatment
- Blog: B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
- Blog: The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
- Blog: Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
- Blog: Cancer stem cells: a target for overcoming therapeutic resistance and relapse
- Blog: Comprehensive Overview of CAR-T Cell Therapy, Engineering Process and Future Prospects
- Blog: Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy
- Blog: 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
- Blog: Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo
- Blog: Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy
History & citation
Current · Permanent link
- This direction split from Engineering Precision to Overcome On-Target Off-Tumor Toxicity (72% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_on_target_off_tumor_toxicity_5a61c41f,
title = {on-target off-tumor toxicity},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/on-target-off-tumor-toxicity/rdr_5a61c41fcb6f4dc1af4d66ad0426b8ac},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}This exact version (version 1, frozen text):
@misc{lacuna_on_target_off_tumor_toxicity_5a61c41f_v1,
title = {on-target off-tumor toxicity},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/on-target-off-tumor-toxicity/rdr_5a61c41fcb6f4dc1af4d66ad0426b8ac/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}